Effectiveness and Safety of Antithrombotic Medication in Patients With Atrial Fibrillation and Intracranial Hemorrhage: Systematic Review and Meta-Analysis

Elena Ivany, MRes; Leona A. Ritchie, MPharm; Gregory Y.H. Lip, MD; Robyn R. Lotto, PhD; David J. Werring, PhD; Deirdre A. Lane, PhD

BACKGROUND: For patients with atrial fibrillation who survive an intracranial hemorrhage (ICrH), the decision to offer oral anticoagulation (OAC) is challenging and necessitates balancing risk of thromboembolic events with risk of recurrent ICrH.

METHODS: This systematic review assesses the effectiveness and safety of OAC and/or antiplatelets in patients with atrial fibrillation with nontraumatic ICrH. Bibliographic databases CENTRAL, MEDLINE, EMBASE, and CINAHL were searched. Articles on adults with atrial fibrillation with spontaneous ICrH (intracerebral, subdural, and subarachnoid), receiving antithrombotic therapy for stroke prevention were eligible for inclusion.

RESULTS: Twenty articles (50,470 participants) included 2 randomized controlled trials (n=304), 8 observational studies, 8 cohort studies, and 2 studies that meta-analyzed individual-level data from observational studies. OAC therapy was associated with a significant reduction in thromboembolic events (summary relative risk [sRR], 0.51 [95% CI, 0.30–0.86], heterogeneity I²=2%; P=0.39, n=5 studies) and all-cause mortality (sRR, 0.52 [95% CI, 0.38–0.71], heterogeneity I²=0%; P=0.44, n=3 studies). OAC therapy was not associated with an increased risk of recurrent ICrH (sRR, 1.44 [95% CI, 0.38–5.46], heterogeneity I²=70%; P=0.02, n=5 studies). Nonvitamin K antagonist OACs were more effective at reducing the risk of thromboembolic events (sRR, 0.65 [95% CI, 0.44–0.97], heterogeneity I²=72%; P=0.03, n=3 studies) and were associated with a lower risk of recurrent ICrH (sRR, 0.52 [95% CI, 0.40–0.67], heterogeneity I²=0%; P=0.43, n=3 studies) than warfarin.

CONCLUSIONS: In nontraumatic ICrH survivors with atrial fibrillation, OAC therapy is associated with a reduced risk of thromboembolic events and all-cause mortality without significantly increasing risk of recurrent ICrH. This finding is primarily based on observational data, and further larger randomized controlled trials are needed to corroborate or refute these findings.

GRAPHIC ABSTRACT: A graphic abstract is available for this article.

Key Words: anticoagulant ■ atrial fibrillation ■ intracranial hemorrhage ■ ischemic stroke ■ systematic review
Nonstandard Abbreviations and Acronyms

<table>
<thead>
<tr>
<th>Nonstandard Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AF</td>
<td>atrial fibrillation</td>
</tr>
<tr>
<td>ICH</td>
<td>intracerebral hemorrhage</td>
</tr>
<tr>
<td>ICrH</td>
<td>intracranial hemorrhage</td>
</tr>
<tr>
<td>NOAC</td>
<td>nonvitamin-K antagonist oral anticoagulant</td>
</tr>
<tr>
<td>OAC</td>
<td>oral anticoagulant</td>
</tr>
<tr>
<td>RCT</td>
<td>randomized controlled trial</td>
</tr>
<tr>
<td>RR</td>
<td>relative risk</td>
</tr>
<tr>
<td>VKA</td>
<td>vitamin-K antagonist</td>
</tr>
</tbody>
</table>

an ischemic stroke, particularly if AF is present. As a result, the clinical dilemma about what, if any, stroke prevention therapy should be offered to ICrH survivors with AF persists. There are few published data from randomized controlled trials (RCTs), and most of the available evidence is from observational studies.

This review aims to systematically assess the effectiveness and safety of OAC in patients with AF who have sustained a nontraumatic ICrH.

METHODS

Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.

Eligibility Criteria
The review was conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and was registered with the PROSPERO database of systematic reviews (REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: CRD42020223266).

Participants
To be eligible for inclusion, articles had to report on adults (aged ≥18 years) with AF who had survived a nontraumatic spontaneous ICrH of any size and any type (lobar, brain stem, deep, cerebellar, subdural, epidural or subarachnoid location; see Table S1 for definitions of terms) or had cerebral microbleeds.

Intervention
The intervention of interest was long-term OAC and/or antiplatelets for stroke prevention in AF. Short-term and/or nonoral anticoagulation therapy or OAC for other reasons were excluded.

Comparators
Any form of oral, long-term anticoagulation therapy and/or antiplatelet therapy, or no comparator (no therapy) were considered.

Outcomes
The primary outcomes were thromboembolic events and recurrent ICrH. Thromboembolic events were chosen as an outcome to reflect the range of definitions used in the included studies (eg, ischemic stroke and/or systemic embolism, and thromboembolic events). Secondary outcomes were major bleeding, all-cause mortality, cardiovascular mortality, fatal hemorrhage or stroke, incidence of clinically significant nonmajor bleeding or thromboembolic events (other than ischemic stroke).

Search Strategy
The following electronic databases were searched: CENTRAL (29/06/20, 07/12/20, and 25/10/21), MEDLINE (03/07/20, 25/10/20, and 25/10/21), EMBASE and CINAHL (30/06/20, 25/09/20, and 25/10/21). Search terms and index terms associated with AF, intracerebral hemorrhage (ICH), major bleeding, and anticoagulant medications were included (Table S2). Only full-text articles were included. Searches were not limited by language but were restricted to the year 2000 onward.

Study Selection
Two researchers (E.I. and L.A.R.) independently assessed the suitability of articles for inclusion against the eligibility criteria. Any disagreements were resolved through examination of the original data and discussion, with recourse to a third reviewer (D.A.L.) where necessary.

Risk of Bias Assessment
Observational studies were assessed using the Risk of Bias Assessment Tool for Nonrandomized Studies (RoBANS) and RCTs were assessed using the Cochrane Collaboration’s tool for assessing risk of bias independently by 2 researchers (E.I. and L.A.R.).

Data Synthesis
Included studies were assessed for clinical and statistical heterogeneity. Meta-analyses were performed if studies reported similar designs, had the same outcomes, comparable interventions and comparators, and pooling the results was appropriate. Studies that could not be included in meta-analyses are reported narratively.

Statistical Analysis
A random effects model was used in all meta-analyses. Event data for control and intervention groups was compared using risk ratios and associated 95% CIs. Sensitivity analyses were performed according to outcome and follow-up period, where appropriate.

Statistical heterogeneity was evaluated using the I² statistic. An I² value of 0% to 40% indicated low heterogeneity, 30% to
60% moderate heterogeneity, 50% to 90% substantial heterogeneity, and ≥75% considerable heterogeneity.

RESULTS
The searches identified 4429 citations, and 4 titles were identified through hand-searching. After removal of duplicates, 3053 titles and 211 abstracts were assessed for eligibility. Reasons for exclusion at the abstract and full-text stages are provided in Figure 1. A total of 20 articles were included in the review.

Characteristics of the Included Studies
The systematic review included articles published between 2015 and 2021, comprising a total of 50,470 participants (mean age ranging from 67.9 years to 83.6 years; 24% to 71.3% female, ICrH sustained on OAC ranging from 0% to 100%). Eight articles reported on prospective observational cohorts, 6 on retrospective cohorts, 2 on nationwide cohorts, 2 meta-analyzed individual-level data from observational studies, 1 reported on the pilot phase of an RCT, and 1 reported on a Phase 2 trial (Table S3). Nine studies included patients with an index ICrH (intracerebral, subdural, subarachnoid, or epidural hemorrhages) and 11 studies included patients with an index ICh. Eight studies could not be included in meta-analyses, either due to differences in reported outcomes or because raw event data were not available.

The included articles reported on a mixture of OAC-naive patients and patients who had their index event while on OAC and/or antiplatelets. The intervention ranged from vitamin-K antagonist (VKA) only, nonvitamin K antagonist oral anticoagulants (NOAC) only, a mixture of VKA and NOAC, or OAC and/or antiplatelets. The most commonly reported outcomes were ischemic stroke and recurrent ICrH. There were variations in how the outcome of ischemic stroke was defined, including cerebral infarct, ischemic stroke, thromboembolic events, major vascular events, and the combined outcome of ischemic event/systemic embolism (Table).

Primary Outcomes
Thromboembolic Events
Seventeen articles (n=35,441) reported on the primary outcome of ischemic stroke/systemic embolism or alternative definitions of stroke. Of these, 9 studies reported on ischemic stroke alone, 5 on ischemic stroke/systemic embolism combined, 1 on thromboembolic events, 1 on ischemic stroke combined with transient ischemic attack (TIA), and 1 on cerebral infarction. One article included OAC-naive participants. Eight included participants who sustained an ICrH on OAC and/or antiplatelets, and 8 included a combination of both OAC-naive and current OAC users. Follow-up ranged from a median of 17 days to a median of 48.6 months.

Oral Anticoagulation Versus No Therapy
Five studies (n=1187 participants) compared the effect of OAC with no therapy on the risk of thromboembolic events (defined in the included articles as cerebral infarction, ischemic stroke, ischemic stroke/systemic embolism) and were entered into a meta-analysis (Figure 2A), which revealed a significant reduction in thromboembolic events with OAC compared with no therapy (relative risk [RR], 0.51 [95% CI, 0.30–0.86]; P=0.01, I²=2%).

Three studies could not be entered into a meta-analysis, either because raw event data were not available or because the study compared the effect of OAC therapy solely in patients with lobar and nonlobar ICH (with no control group). Nielsen et al reported that OAC therapy was associated with a nonsignificant reduction in the rate of ischemic stroke and systemic embolism compared with no therapy (event rate 3.3 versus 8.9 per 100 person-years, adjusted HR, 0.49 [95% CI, 0.24–1.02]). Biffi et al reported that restarting VKA was associated with a reduced risk of sustaining an ischemic stroke in both lobar (HR, 0.48 [95% CI, 0.25–0.75]; P=0.003) and nonlobar (HR, 0.39 [95% CI, 0.21–0.74]; P=0.004) ICH patients. Newman et al reported no statistical significance between the OAC and no therapy groups for the outcome of stroke/TIA (adjusted HR, 0.87 [95% CI, 0.62–1.21]).

Oral Anticoagulation and/or Antiplatelets Versus No Therapy
Three observational studies compared OAC and/or antiplatelets with no therapy and reported on the outcome of ischemic events. The study by Pennlert et al was not included in the meta-analysis due to unavailability of raw event data. The pooled relative risk for the other 2 studies (n=13,063) was RR, 0.93 [95% CI, 0.43–2.04]; P=0.87, I²=77% (Figure 2B).

Oral Anticoagulation Versus Antiplatelets or No Therapy
Three observational studies (n=17,287) and 2 RCTs (n=304) compared OAC versus antiplatelet or no therapy. Three studies were included in a meta-analysis, which found no significant difference in the risk of thromboembolic events between OAC and antiplatelet or no therapy (RR, 0.58 [95% CI, 0.23–1.46]; P=0.25, I²=74%; Figure 2C).

Two studies could not be entered into the meta-analysis due to lack of raw event data. Pennlert et al reported that the cumulative incidence of thromboembolic events 3-years post-index ICH was 6.3% in patients assigned to OAC versus 18.8% in the antiplatelet group and 13.8% in the no therapy group. Nielsen et al reported that the
incidence rate of ischemic stroke/systemic embolism, per 100 person-years, was 5.3 (95% CI, 3.3–8.5) in the OAC group, 10.3 (95% CI, 7.3–14.4) in the antiplatelet group, and 10.4 (95% CI, 8.2–13.1) in the no therapy group.

**NOAC Versus Warfarin**

Three studies (n=8711) compared NOAC with warfarin and reported a significant reduction in the risk of thromboembolic events with NOAC compared with
<table>
<thead>
<tr>
<th>Author, y, country</th>
<th>Intervention (n)</th>
<th>Comparator (n)</th>
<th>Length of follow-up</th>
<th>Types of ICH included and ICrH diagnosis technique(s)</th>
<th>Number of events: ischemic stroke</th>
<th>Number of events: intracranial/intracerebral hemorrhage</th>
<th>Number of events: all-cause mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee et al,23 2020, Korea</td>
<td>NOAC (n=1115)*</td>
<td>Warfarin (n=2434)</td>
<td>Median, year 0.6 (IQR, 0.2–1.7)</td>
<td>Intracranial hemorrhage. Diagnosis based on clinical presentation, hospitalization, CT, and/or MRI scan.</td>
<td>NOAC: 45/1115*</td>
<td>Warfarin: 191/2434 HR, 0.729 (95% CI, 0.522–1.017)</td>
<td>NOAC: 19/1115*</td>
</tr>
<tr>
<td>Tsai et al,26 2020, Taiwan</td>
<td>NOAC (n=3493)</td>
<td>Warfarin (n=1047)</td>
<td>Not reported</td>
<td>Intracranial hemorrhage. Diagnosis method not reported (data from registry).</td>
<td>NOAC: 226/3493</td>
<td>Warfarin: 78/1047 aHR, 0.879 (95% CI, 0.678–1.141)</td>
<td>NOAC: 15/348</td>
</tr>
<tr>
<td>Nielsen et al,16 2019, Denmark</td>
<td>NOAC (n=348)</td>
<td>Warfarin (n=274)</td>
<td>1 and 3 y</td>
<td>Intracerebral hemorrhage. Diagnosis method not reported (data from registry).</td>
<td>NOAC: 15/348</td>
<td>Warfarin: 21/274 Weighted risk difference, 3.78% (95% CI, −0.15% to 7.71%)*</td>
<td>NOAC: 682/3493</td>
</tr>
<tr>
<td>Sadighi et al,20 2020, United States</td>
<td>Warfarin or NOAC (n=38)</td>
<td>No therapy (n=55)</td>
<td>Mean, mo OAC: 22.7 (22.4) No OAC: 28.8 (22.0)</td>
<td>Spontaneous nontraumatic intracerebral hemorrhage. Initial method of diagnosis not reported.</td>
<td>OAC: 7/38†</td>
<td>No therapy: 10/55 RR, 0.9 (95% CI, 0.3–2.7)</td>
<td>OAC: 5/38</td>
</tr>
<tr>
<td>Sakamoto et al,9 2019, Japan</td>
<td>VKA or NOAC (n=29)</td>
<td>No therapy (n=4)</td>
<td>To hospital discharge</td>
<td>Lobar or nonlobar intracerebral hemorrhage. Brain imaging (CT/MRI) available for all participants.</td>
<td>OAC: 2/29</td>
<td>No therapy: 0/4 HR not reported</td>
<td>OAC: 0/29</td>
</tr>
<tr>
<td>Perreault et al,13 2019, Canada</td>
<td>VKA or NOAC (n=125)</td>
<td>No therapy (n=249)</td>
<td>1 y</td>
<td>Intracranial hemorrhage. Initial method of diagnosis not reported.</td>
<td>OAC: 1/125†</td>
<td>No therapy: 7/247 HR not reported</td>
<td>OAC: 4/123</td>
</tr>
<tr>
<td>Park et al,12 2016, Korea</td>
<td>Warfarin (n=254)</td>
<td>No therapy (n=174)</td>
<td>Mean, mo 39.5±31.9</td>
<td>Cerebral (47%), subdural (36.4%), subarachnoid (11%), cerebellar (3%), epidural (0.7%), intraventricular (0.7%) hemorrhages. Diagnosed by clinical presentation, CT, and/or MRI scan.</td>
<td>Warfarin: 7/254</td>
<td>No therapy: 14/174 RR, 0.19 (95% CI, 0.08–0.47)</td>
<td>Warfarin: 13/254§</td>
</tr>
<tr>
<td>Kura-matsu et al,11 2015, Germany</td>
<td>VKA (n=108)</td>
<td>No therapy (n=153)</td>
<td>1 y</td>
<td>Deep (45.1%), lobar (37.1%), cerebellar (10.3%), brain stem (4.3%), intraventricular (3.2%) hemorrhages. Diagnosed using brain imaging (CT/MRI).</td>
<td>VKA: 4/108†</td>
<td>No therapy: 16/153 HR not reported</td>
<td>VKA: 4/108</td>
</tr>
</tbody>
</table>

(Continued)
### Antithrombotics Post-Intracranial Hemorrhage in AF

<table>
<thead>
<tr>
<th>Author, y, country</th>
<th>Intervention (n)</th>
<th>Compari-son (n)</th>
<th>Length of follow-up</th>
<th>Types of ICrH included and ICrH diagnosis technique(s)</th>
<th>Number of events: ischemic stroke</th>
<th>Number of events: intracranial/intracerebral hemorrhage</th>
<th>Number of events: all-cause mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chao et al., 2016, Taiwan</td>
<td>Warfarin (n=1154) or antiplatelet (n=3552)</td>
<td>No therapy (n=8211)</td>
<td>Mean, y, 3.3±3.6</td>
<td>Intracerebral (68.6%), subarachnoid (12.3%), epidural (2.5%), subdural (12.6%), nonspecified (4%) hemorhages. Diagnosis method not reported (registry data).</td>
<td>Warfarin: 130/1154 aHR, 0.66 (95% CI, 0.55–0.79)</td>
<td>Antiplaletet: 581/3552 aHR, 0.90 (95% CI, 0.81–1.01)</td>
<td>No therapy: 954/8211 aHR, 1</td>
</tr>
<tr>
<td>Chao et al., 2018, Italy</td>
<td>Warfarin or NOAC (n=55) or antiplatelet (n=28)</td>
<td>No therapy (n=62)</td>
<td>Median, mo 18.0</td>
<td>Lobar (cortex or cerebellar) and nonlobar (basal ganglia, thalamus, or brain stem) intracerebral hemorrhages. Diagnosed by CT or MRI scan.</td>
<td>OAC: 2/55† wHR, 0.09 (95% CI, 0.02–0.40)</td>
<td>Antiplaletet: 8/29 wHR, 1.07 (95% CI, 0.40–2.83)</td>
<td>No therapy: 13/62 wHR, 1</td>
</tr>
<tr>
<td>APACHE-AF Investigators, 2021, the Netherlands</td>
<td>Apixaban (n=50)</td>
<td>Antiplatelet or no therapy (n=61)</td>
<td>Median, 1.9 y (IQR, 1.0–3.1)</td>
<td>Lobar, nonlobar, brain stem, cerebellar, and intraventricular intracerebral hemorrhages. Diagnosis confirmed by imaging (not defined).</td>
<td>Apixaban: 8/50 Antiplatelets or no therapy: 6/61 aHR, 0.96 (95% CI, 0.31–2.97)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SoSTART Collaboration, 2021, United Kingdom</td>
<td>NOAC or VKA (n=101)</td>
<td>Antiplatelet or no therapy (n=102)</td>
<td>Median, 1.2 y (IQR, 0.87–1.95)</td>
<td>Lobar and nonlobar spontaneous intracerebral, nonaneurysmal subarachnoid, intraventricular or subdural hemorrhage. Diagnosis confirmed by CT or MRI scan.</td>
<td>OAC: 3/101 Antiplatelets or no therapy: 19/102 HR not available</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

AF indicates atrial fibrillation; aHR, adjusted hazard ratio; CT, computed tomography; HR, hazard ratio; ICD-10, International Classification of Diseases and Health Related Problems, Tenth Revision; ICrH, intracranial hemorrhage; IQR, interquartile range; MRI, magnetic resonance imaging; N/A, not available; NOAC, nonvitamin K antagonist oral anticoagulant; OAC, oral anticoagulant; RR, relative risk; VKA, vitamin K antagonist; and wHR, weighted hazard ratio.

*Participant numbers and event rates given are before propensity matching.
†Outcome reported is ischemic stroke/systemic embolism.
‡Participant numbers reported for participants with AF only.
§Outcome reported is recurrent CNS bleeding.
¶Outcome reported is cerebral infarction.
∥Event rate data reported is after propensity matching.
¶†Outcome reported is recurrent CNS bleeding.
††Outcome reported is cerebral infarction.
warfarin (RR, 0.65 [95% CI, 0.44–0.97]; P=0.03, I²=72%) but there was considerable heterogeneity (Figure 2D).

Recurrent ICrH
Fifteen studies7–9,12–16,20,22–27 (n=32,579 patients with AF and ICrH) reported on the outcome of recurrent ICrH. Eight studies8,13–15,23–26 included patients with an index ICrH (intracerebral, subdural, subarachnoid, or epidural hemorrhages) and 7 studies8,14,16,20,22,27 included patients with an index ICH. One study included OAC-naive participants,23 7 studies included participants who sustained an ICrH on OAC,8,15,20,22,24,26,27 and 7 studies included a combination of OAC-naive patients and patients who sustained an ICrH on OAC.8,9,12–14,16,28 Follow-up ranged from a median of 17 days9 to a median 48.6 months.27

Oral Anticoagulation Versus No Therapy
Five observational studies (n=1187)9,12,13,20,22 compared OAC versus no therapy on the risk of sustaining a recurrent ICrH and the pooled estimate revealed no statistically significant difference (RR, 1.44 [95% CI, 0.38–5.46]; P=0.59, I²=70%; Figure 3A).

Three observational studies could not be entered into a meta-analysis,15,24,27 Biffi et al27 reported that VKA resumption was associated with a nonsignificant increase in the risk of sustaining an ICH (lobar HR, 1.21 [95% CI, 0.86–1.70]; P=0.27; nonlobar HR, 1.10 [95% CI, 0.94–1.28]; P=0.23). Nielsen et al15 reported that warfarin treatment was associated with a nonsignificant increase in the risk of recurrent ICrH (adjusted HR, 1.31 [95% CI, 0.68–2.50]). Newman et al35 reported an association between OAC therapy (VKA or NOAC) post-ICH and a reduction in the risk of recurrent ICrH (incidence 3.29 versus 5.80 events per 100 patient-years, adjusted HR=0.62 [95% CI, 0.41–0.95]).

Oral Anticoagulation Versus Antiplatelets or No Therapy
Two RCTs78 (n=304) and 2 observational studies14,26 (n=14,669) compared OAC versus antiplatelet therapy or no therapy. Three studies78,26 (n=13,221) were entered into a meta-analysis; OAC was associated with a higher risk of recurrent ICrH versus antiplatelet or no therapy (RR, 1.82 [95% CI, 1.61–2.05]; P<0.01, I²=0%; Figure 3B).

Nielsen et al.14 reported that the incidence rate of recurrent ICrH per 100 person-years, was 8.0 (95% CI, 5.4–11.8) in the OAC group, 5.3 (95% CI, 3.3–8.4) in the antiplatelet group, and 8.6 (95% CI, 6.6–11.2) in the no therapy group.

NOAC Versus Warfarin
Three studies (n=871)16,26 compared the effect of NOAC versus warfarin on recurrent ICrH with the pooled relative risk demonstrating that NOAC significantly reduced risk of recurrent ICrH compared with warfarin (RR, 0.52 [95% CI, 0.40–0.67]; P<0.00001, I²=0%; Figure 3C).

Secondary Outcomes
All-Cause Mortality
Five observational studies (n=11,456)12,13,20,22,26 and 2 RCTs78 (n=304) reported on all-cause mortality. Three studies included patients who had sustained their index ICrH on OAC20,26 1 study included OAC-naive patients,23 and another 3 included a mixture of OAC-naive patients and patients who sustained their ICrH on OAC8,12,13 Two studies included patients who sustained an index ICH25 and 5 articles included patients who sustained an index ICh.8,12,13,20,26

The longest follow-up was median 39.9 months.22

Oral Anticoagulation Versus No Therapy
Three studies (n=891)12,13,20 examined the impact of OAC versus no therapy on all-cause mortality and reported a significant reduction in death associated with OAC (RR, 0.52 [95% CI, 0.36–0.71]; P<0.01, I²=0%; Figure 4A).

Oral Anticoagulation Versus Antiplatelets or No Therapy
Two RCTs (n=304) examined the impact of OAC versus antiplatelets or no therapy on all-cause mortality and were entered into a meta-analysis, which was not statistically significant (RR, 1.09 [95% CI, 0.64–1.87]; P=0.74, I²=0%; Figure 4B).

NOAC Versus Warfarin
Two studies (n=8089)23,26 examined the impact of NOAC versus warfarin on the risk of all-cause mortality and the pooled estimate demonstrated that NOACs were significantly associated with a reduced risk of all-cause mortality (RR, 0.55 [95% CI, 0.41–0.74]; P=0.00001, I²=81%; Figure 4C).

Subgroup and Sensitivity Analyses
Subgroup and sensitivity analyses are provided in Table S4. OAC therapy significantly reduced the risk of thromboembolic events at 1 year follow-up (RR, 0.34 [95% CI, 0.13–0.87], I²=0%) but not at > 1 year (RR, 0.59 [95% CI, 0.20–1.72], I²=66%). The risk of sustaining a recurrent ICRH did not differ by follow-up time. Examining only the RCT data78 (n=304), no difference was found in the risk of ischemic stroke (RR, 0.41 [95% CI, 0.06–2.64], I²=82%) or recurrent ICH (RR, 2.37 [95% CI, 0.85–6.62], I²=0%) when comparing OAC with antiplatelet or no therapy.

Risk of Bias Assessment
The overall risk of bias assessment for all included studies is presented in Figures S1 and S2. The categories addressing participant selection, incomplete outcome data, and selective outcome reporting among observational studies were assessed as having the lowest risk of bias.

DISCUSSION
This systematic review included 20 studies (n=50,470, 304 were enrolled in RCTs) and updates previously...
Our main findings are that OAC significantly reduced the risk of thromboembolic events and all-cause mortality in patients with AF and ICH, without significantly increasing the risk of recurrent ICH. Second, NOACs were associated with a lower risk of thromboembolic events and recurrent ICH than warfarin.

**Oral Anticoagulation for Stroke Prevention**

This PRISMA-compliant systematic review found that OAC therapy significantly reduced the risk of an ischemic stroke in patients with AF and a history of ICH when compared with no therapy (RR, 0.51 [95% CI, 0.30–0.86]; P=0.01). Previous meta-analyses that investigated the effect of restarting OAC post-ICH reported that OAC generally and VKA specifically were associated with a reduction in thromboembolic events.29,30,32 The current review also found that NOAC therapy is more effective at preventing thromboembolic events than warfarin (RR, 0.65 [95% CI, 0.44–0.97]). Although trials comparing NOAC and warfarin largely excluded patients with ICH, and findings in this review are based on observational data, there is evidence to suggest that NOACs are more effective at preventing thromboembolic events than warfarin.33 However, 2 recently completed RCTs found that restarting OAC was not associated with a significant decrease in the risk of thromboembolic events in patients with AF and a history of ICH or ICRH.7,8

**Oral Anticoagulation and All-Cause Mortality**

The significant reduction in all-cause mortality among patients with AF who received OAC therapy following ICH compared with those who received no therapy.
supports the use of OAC in the post-ICrH population with AF. This finding is confirmed by a previous meta-analysis that examined OAC resumption in patients who sustained an OAC-associated ICrH. The main limitation with assessing the impact of OAC therapy following ICrH is confounding by indication, as studies have shown differences between those who did and those who did not receive OAC post-ICrH. Two studies reported that patients exposed to OAC at the time of their ICrH were less likely to restart OAC post-ICrH. It is possible that OAC is associated with improved survival in AF patients post-ICrH as OAC is more likely to be prescribed to those who are more likely to survive. However, OAC use post-ICrH has been shown to be associated with improved functional outcomes among patients with poor functional status (modified Rankin Scale score >3) at hospital discharge.

Oral Anticoagulation and the Risk of Recurrent ICrH

The current review found that OAC therapy was not associated with a statistically significantly increased risk of recurrent ICrH (RR, 1.44 [95% CI, 0.38–5.46]; P=0.59). Of the 10 studies examining the association between OAC and/or antiplatelet therapy and the risk of recurrent ICrH, 2 studies reported a significant increase in the risk of an ICrH (defined in 1 article as CNS bleeding), 2 studies reported a reduction in the risk of repeat ICrH, and 6 studies reported no significant difference in the risk of recurrent ICrH. There was heterogeneity in the type of OAC therapy used and the baseline characteristics of the patients who were commenced on OAC therapy. Furthermore, there was considerable heterogeneity in the participant cohorts and follow-up periods reported, and an unclear risk of bias regarding measurement of participants’ exposure to OAC therapy in all but one of the included articles.

From the patient’s perspective, the key attribute of OAC therapy is stroke prevention, although risk of bleeding is the second most important attribute when choosing OAC. However, patients report variability in the number of acceptable bleeds associated with OAC therapy and considerable differences in the percentage of patients who were not willing to consider OAC therapy. The study by Chao et al reported that...
patients who survive an ICrH are at increased risk of repeat ICrH regardless of whether they receive OAC therapy post-ICrH or not, and that OAC therapy with VKA post-ICrH ought to be reserved for patients with CHA2DS2-VASc ≥6. NOACs may alleviate some concerns about OAC-related ICrH because apixaban and dabigatran have been shown to be associated with reduced risk of major bleeding when compared with warfarin, and NOACs have reversal agents which may prevent exacerbating the ICrH. However, results from APACHE-AF show that there were more recurrent ICH in the apixaban group than in the antiplatelet or no therapy group (8% versus 2%), although this difference was not significant (adjusted hazard ratio, 4.08 [95% CI, 0.45–36.91]). Furthermore, SoSTART reported that OAC could not be considered noninferior to no therapy due to the increased risk of mortality and recurrent ICrH.

Strengths and Limitations of This Review

Several bibliographic databases were searched to ensure that all contemporary relevant literature was captured, and 2 authors independently selected the included studies and extracted the data. Sensitivity analyses and subgroup analyses were undertaken.

The primary limitation of this review is that most are observational cohort studies. The included studies were heterogeneous, both clinically and methodologically, with most reporting on both intracerebral and other types of ICrH combined. This is a limitation since intracerebral (or parenchymal) hemorrhage is associated with a higher intrinsic risk of thrombotic events than subarachnoid hemorrhage. In addition, not all studies could be included in the meta-analyses due to unavailable data or differences in reported outcomes. Finally, it was difficult to accurately assess the measurement of participants’ exposure to OAC therapy, since several studies were retrospective in design and utilized patient data from large databases. Therefore, the results of this systematic review should be interpreted with caution. Several RCTs addressing the efficacy and safety of OAC for stroke prevention in patients with AF who have survived an ICH or ICrH are ongoing. The findings reported by these RCTs will be critical to confirm or refute the findings of this review.

CONCLUSIONS

OAC use after ICrH in patients with AF significantly reduces the risk of thromboembolic events and all-cause mortality, without significantly increasing the risk of recurrent ICrH. NOACs are preferable to warfarin as they...
are associated with preventing thromboembolic events with a lower risk of recurrent ICH. Nevertheless, the available evidence is mostly observational, with considerable clinical and methodological heterogeneity, including differences in intervention, comparators, outcomes, and follow-up time. Thus, further evidence from ongoing RCTs is urgently needed to corroborate these findings.

**ARTICLE INFORMATION**

Received January 18, 2022; final revision received May 5, 2022; accepted May 25, 2022.

**Disclosures**

E. Ivany is a Research Associate on the PRESTIGE-AF study, which has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No. 754517. Dr Lane has received investigator-initiated educational grants from Bristol-Myers Squibb (BMS), has been a speaker for Bayer, Boehringer Ingelheim, and BMS/Pfizer initiatives, and has consulted for BMS and Boehringer Ingelheim. Dr Lane is a co-investigator on the PRESTIGE-AF study, which has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No. 754517. Dr Lip is a consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, and BMS/Pfizer initiatives, and has consulted for BMS, and Boehringer Ingelheim. Dr Lane is a co-investigator on the PRESTIGE-AF study, which has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No. 754517. Dr Lip was part of the steering committee for the SoSTART study, which has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No. 754517. Dr Lip is a consultant and speaker for BMS, and Boehringer Ingelheim. Dr Lane is a co-investigator on the PRESTIGE-AF study, which has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No. 754517.

**Acknowledgments**

The authors would like to thank Dr Yuki Sakamoto and colleagues for their provision of supplementary data to accompany the article included in the review.

**Sources of Funding**

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 754517.

**REFERENCES**


